ONO-4578-08 trial: what clinicians have said so far
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
- NCT06256328 ↗
- Active, not recruiting
- Ono Pharmaceutical Co., Ltd.
- Focused size, estimated: 1–150 verified statements once built
Discussed at: 2026 ASCO Annual Meeting
We haven't built an HCP commentary report on ONO-4578-08 (ONO-4578 plus nivolumab in chemotherapy-naïve HER2-negative unresectable advanced or recurrent gastric cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 9 indexed sources
Automated from all 9 indexed sources (Apr 2026 – Jun 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether the effect of adding ONO-4578 differs by PD-L1 CPS, and which cutoff defines who might benefit
- Whether adding ONO-4578 to nivolumab plus chemotherapy delays progression compared with placebo
- Whether ONO-4578 improves overall survival once follow-up matures
- Whether adding ONO-4578 changes the serious adverse event burden of nivolumab plus chemotherapy
Indexed commentary on ONO-4578-08 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 9 posts on X, typically up to 40 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Multicenter, Double-blind, Phase II Study to Compare the Efficacy and Safety of the Treatment With ONO-4578 in Combination With Nivolumab, Fluoropyrimidine-based and Platinum- Based Chemotherapy (Hereinafter Referred to as Chemotherapy) With Those of the Treatment With Placebo in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Gastric Cancer
- Interventions
- ONO-4578; Oxaliplatin; Capecitabine; S-1; Nivolumab; Placebo
- Arms
- ONO-4578+Nivolumab+chemotherapy · Experimental
- placebo+Nivolumab+chemotherapy · Placebo comparator
- Enrollment
- 226
- Primary outcomes
- Progression-free survival (PFS) (site investigator assessment)
- Sponsor
- Ono Pharmaceutical Co., Ltd.
- Start
- Jan 10, 2024
- Primary completion
- Oct 9, 2025
- Results posted
- No
- Registry record
- NCT06256328 · updated Mar 13, 2026
Publications
linked from the registry- Nakayama I, Ryu MH, Lim SH, Kim JG, Omori T, Oh SC, Kim JY, Rha SY, Lee KW, Machida N, Sym SJ, Narita Y, Park YI, Hara H, Hosaka H, Kang B, Kim IH, Bai LY, Hirashima Y, Hagihara S, Yamamoto T, Shitara K. EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. J Clin Oncol. 2026 Aug 10;44(23):2198-2210. doi: 10.1200/JCO-26-01072. Epub 2026 Jun 1. PubMed 42223130